AbbVie Inc (NYSE:ABBV) has sought a joint venture with its target discovery portfolio company, Emergent Technologies Inc, Pure MHC. The collaboration between the two will seek to identify a library of peptide targets that will necessitate further research across multiple tumor types.
AbbVie’s pipeline spans significant areas of medical need the likes of oncology, immunology, neuroscience and virology. This is why Chief Executive Officer at ETI and Pure MHC Thomas Harlan acknowledges, “We are excited to partner with AbbVie in the immuno-oncology space leveraging Pure MHC’s over 15 years of peptide target discovery with AbbVie’s deep clinical expertise to utilize these targets in new and improved therapies for the treatment of cancer.”
Combined efforts hope to accelerate the pace of innovation
Innovation has fully become the key driver of the world even in the simplest of tasks. Hence combined efforts are important according to AbbVie’s research and development and chief scientific officer Michael Severino. He emphasizes that the development of tomorrow’s therapies is dependent on today’s investment in leading technologies and scientific achievements. It will also facilitate an enhanced pace of innovation into new medicines for the next-generation of medical treatment.
Assistant Vice President, Office of Technology Development at the University of Oklahoma, James Bratton agrees that the Pure MHC team and Emergent Technologies have the vision, expertise, and dedication required to deliver a lasting, positive impact on the world.
AbbVie explores an additional collaboration with Dong-A-ST
AbbVie will not just rest at its collaboration with Pure MHC. It has spread its wings to Dong-A ST Co Ltd, a leading specialty healthcare company in South Korea. This collaboration will investigate the combination of MerTK inhibitors together with AbbVie’s portfolio of anti-cancer agents. MerTK is a protein assumed to add to the back-up of immunosuppressive tumor microenvironment.
The addition of this method will press on AbbVie’s accessible research into immuno-oncology therapies. It will also help in complementing its oncology pipeline under development for nearly 20 cancers and tumor types. Meanwhile, AbbVie’s stock closed at $64.21 for an increase of $0.42 or 0.66%.